CN115836129B - 用于治疗tdp-43蛋白病的组合物和方法 - Google Patents
用于治疗tdp-43蛋白病的组合物和方法Info
- Publication number
- CN115836129B CN115836129B CN202180045995.1A CN202180045995A CN115836129B CN 115836129 B CN115836129 B CN 115836129B CN 202180045995 A CN202180045995 A CN 202180045995A CN 115836129 B CN115836129 B CN 115836129B
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- tdp
- domain
- nucleic acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202610632651.5A CN122444887A (zh) | 2020-04-28 | 2021-04-27 | 用于治疗tdp-43蛋白病的组合物和方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016707P | 2020-04-28 | 2020-04-28 | |
| US63/016707 | 2020-04-28 | ||
| US202063035437P | 2020-06-05 | 2020-06-05 | |
| US63/035437 | 2020-06-05 | ||
| PCT/US2021/029289 WO2021222168A2 (en) | 2020-04-28 | 2021-04-27 | Compositions and methods for the treatment of tdp-43 proteinopathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610632651.5A Division CN122444887A (zh) | 2020-04-28 | 2021-04-27 | 用于治疗tdp-43蛋白病的组合物和方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115836129A CN115836129A (zh) | 2023-03-21 |
| CN115836129B true CN115836129B (zh) | 2026-05-26 |
Family
ID=75905076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180045995.1A Active CN115836129B (zh) | 2020-04-28 | 2021-04-27 | 用于治疗tdp-43蛋白病的组合物和方法 |
| CN202610632651.5A Pending CN122444887A (zh) | 2020-04-28 | 2021-04-27 | 用于治疗tdp-43蛋白病的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610632651.5A Pending CN122444887A (zh) | 2020-04-28 | 2021-04-27 | 用于治疗tdp-43蛋白病的组合物和方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240327477A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4143215A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7894321B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230025659A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115836129B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021265088A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021604A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013288A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202206446A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021222168A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021367952A1 (en) * | 2020-10-26 | 2023-06-08 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
| US20250205305A1 (en) * | 2022-01-27 | 2025-06-26 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and compositions for rescuing protein misfolding |
| WO2023185017A1 (zh) * | 2022-03-30 | 2023-10-05 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 经修饰的rnf112或包含其的外泌体递送系统 |
| CN114874332B (zh) * | 2022-03-30 | 2023-01-10 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 经修饰的rnf112作为治疗als药物的应用 |
| CN122070299A (zh) * | 2023-09-15 | 2026-05-19 | 普罗塞纳生物科学有限公司 | 细胞穿透剂及其用途 |
| WO2025264861A1 (en) * | 2024-06-18 | 2025-12-26 | Yale University | Compositions of bi-functional alpha helical peptides and methods thereof for treating tdp-43 proteinopathies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089375A1 (en) * | 2012-12-05 | 2014-06-12 | Boston Strategics Corporation | Protein expression enhancing polypeptides |
| WO2016086320A1 (en) * | 2014-12-05 | 2016-06-09 | UNIVERSITé LAVAL | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| WO2010111587A1 (en) * | 2009-03-26 | 2010-09-30 | Trustees Of The University Of Pennsylvania | Modulators of tdp-43 mediated toxicity |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| CA2853412C (en) | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| WO2014038884A1 (ko) * | 2012-09-07 | 2014-03-13 | 주식회사 마크로젠 | 융합 단백질 및 이를 포함하는 암 진단용 조성물 |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US20160220649A1 (en) * | 2013-09-13 | 2016-08-04 | Fundación Pública Andaluza Progreso Y Salud | Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases |
| WO2016053610A1 (en) | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| US10720797B2 (en) | 2017-05-26 | 2020-07-21 | California Institute Of Technology | Method and apparatus for dynamic RF lens focusing and tracking of wireless power recovery unit |
| US11466077B2 (en) | 2018-01-05 | 2022-10-11 | Ac Immune Sa | Misfolded TDP-43 binding molecules |
| JP7320282B2 (ja) | 2018-03-16 | 2023-08-03 | 国立大学法人滋賀医科大学 | 異常tdp-43を分解除去する抗体断片 |
-
2021
- 2021-04-27 JP JP2022565544A patent/JP7894321B2/ja active Active
- 2021-04-27 CN CN202180045995.1A patent/CN115836129B/zh active Active
- 2021-04-27 WO PCT/US2021/029289 patent/WO2021222168A2/en not_active Ceased
- 2021-04-27 US US17/997,142 patent/US20240327477A1/en active Pending
- 2021-04-27 CN CN202610632651.5A patent/CN122444887A/zh active Pending
- 2021-04-27 AU AU2021265088A patent/AU2021265088A1/en active Pending
- 2021-04-27 EP EP21725359.0A patent/EP4143215A2/en active Pending
- 2021-04-27 KR KR1020227041465A patent/KR20230025659A/ko active Pending
- 2021-04-27 MX MX2022013288A patent/MX2022013288A/es unknown
- 2021-04-27 BR BR112022021604A patent/BR112022021604A2/pt unknown
- 2021-04-28 TW TW110115416A patent/TW202206446A/zh unknown
-
2026
- 2026-04-16 JP JP2026067788A patent/JP2026123053A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089375A1 (en) * | 2012-12-05 | 2014-06-12 | Boston Strategics Corporation | Protein expression enhancing polypeptides |
| WO2016086320A1 (en) * | 2014-12-05 | 2016-06-09 | UNIVERSITé LAVAL | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230025659A (ko) | 2023-02-22 |
| JP2023524414A (ja) | 2023-06-12 |
| JP2026123053A (ja) | 2026-07-29 |
| TW202206446A (zh) | 2022-02-16 |
| AU2021265088A1 (en) | 2022-11-03 |
| EP4143215A2 (en) | 2023-03-08 |
| CN122444887A (zh) | 2026-07-24 |
| MX2022013288A (es) | 2023-02-22 |
| WO2021222168A3 (en) | 2021-12-30 |
| BR112022021604A2 (pt) | 2022-12-06 |
| WO2021222168A2 (en) | 2021-11-04 |
| US20240327477A1 (en) | 2024-10-03 |
| JP7894321B2 (ja) | 2026-07-23 |
| CN115836129A (zh) | 2023-03-21 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40088984 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |